NewAmsterdam Pharma Co N.V. (NAMS)
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
- Symbol
- NAMS
- Exchange
- Nasdaq
- Sector
- Healthcare
- Industry
- Biotechnology
- Market cap
- $2.74B
- 52 week range
- 21.02 - 42.21
Valuation
- Share price
- $22.68 (close of 2026-09-23)
- P/E (TTM)
- -10.85x
- Price to book
- 4.35x
- Price to free cash flow
- -19.09x
- Enterprise value
- $2.32B
- Book value per share
- $5.37
Price performance
| Period | Change |
|---|
| 1 day | +0.44% |
| 5 days | +7.18% |
| 1 month | -18.62% |
| 3 months | -27.77% |
| 6 months | -24.43% |
| Year to date | -35.35% |
| 1 year | -14.96% |
| 3 years | +141.02% |
| 5 years | +130.25% |
| All time | +113.76% |
Profitability and growth
- Return on equity
- -29.82%
- Return on invested capital
- -116.55%
- Return on assets
- -26.49%
- Return on capital employed
- -33.02%
- Net margin
- -905.74%
- EBITDA margin
- -1000.78%
- Revenue growth
- -50.61%
- Net income growth
- 15.64%
- Free cash flow growth
- 7.04%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- -5.24%
- Current ratio
- 9.03x
- Net debt to EBITDA
- 1.74x
Latest reported year
- Period end
- 2025-12-31
- Fiscal year
- 2025
- Revenue
- $22.50M
- EBITDA
- $-225.21M
- Net income
- $-203.82M
- Earnings per share
- $-1.72
- Research and development
- $141.83M
- Shares outstanding
- 118.42M
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|
| 2025-12-31 | $22.50M | - | $-203.82M | $-1.72 |
| 2024-12-31 | $45.56M | - | $-241.60M | $-2.56 |
| 2023-12-31 | $14.09M | - | $-176.94M | $-2.15 |
| 2022-12-31 | $102.69M | $96.78M | $-22.63M | $-1.19 |
| 2021-12-31 | - | - | $-41.78M | $-3.81 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|
| 2025-12-31 | - | -905.74% | -29.82% | -116.55% |
| 2024-12-31 | - | -530.25% | -31.89% | - |
| 2023-12-31 | - | -1255.76% | -61.35% | - |
| 2022-12-31 | 94.24% | -22.04% | -5.26% | -0.83% |
| 2021-12-31 | - | - | 36.71% | - |
Cash and debt by year
| Period end | Cash |
|---|
| 2025-12-31 | $490.00M |
| 2024-12-31 | $771.74M |
| 2023-12-31 | $340.45M |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|
| 2025-12-31 | $-148.03M | $59.42M |
| 2024-12-31 | $-159.24M | $33.62M |
| 2023-12-31 | $-141.24M | $24.57M |
| 2022-12-31 | $10.44M | $4.12M |
| 2021-12-31 | $-29.54M | $1.24M |
Investor relations
Next earnings report
- Next confirmed report
- 2026-11-04
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|
| 2026-08-05 | Jun/2026 | - |
| 2026-05-07 | - | - |
| 2026-02-18 | - | - |
| 2025-11-05 | - | - |
| 2025-08-06 | - | - |
| 2025-05-08 | - | - |
| 2025-02-26 | - | - |
| 2024-11-06 | - | - |
Filings and sources
- Company website
- newamsterdampharma.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Vertex Pharmaceuticals Inc (VRTX) · Regeneron Pharmaceuticals, Inc. (REGN) · Moderna, Inc. (MRNA) · Incyte Corp (INCY) · Bio-Techne Corp (TECH) · Thermo Fisher Scientific Inc. (TMO) · Danaher Corp (DHR) · IQVIA Holdings Inc. (IQV)
All Healthcare companies
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades